A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
Stopped Development of tasquinimod in prostate cancer discontinued
Conditions
- Metastatic Castrate Resistant Prostate Cancer
Interventions
- DRUG: Tasquinimod
- DRUG: Placebo
Sponsor
Ipsen